About Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is a private company based in Portland, Oregon. It has reported $73,253,980 raised in four offerings on Form D since November 2019. Its chief executive is Robert Jacks.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 20, 2025 | Jul 1, 2025 | $61,841,225of $121.4M target | 17 | $3.6M | EquityRule 506(b) | Form D ↗ |
| Apr 10, 2024 | Apr 12, 2024 | $10,000,000of $15.2M target | 4 | $2.5M | Debt, OptionsRule 506(b) | Form D ↗ |
| Dec 31, 2020 | Jan 13, 2021 | $1,075,255of $50.8M target | 15 | $71,684 | EquityRule 506(b) | Form D ↗ |
| Aug 21, 2018 | Nov 15, 2019amended Jun 26, 2020 | $337,500fully sold | 10 | $33,750 | Debt, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Total, four offerings | $73,253,980 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Sparrow Pharmaceuticals's Form D filed Jul 1, 2025.
JR
Jonathan Root
Director
ND
Niall O'Donnell
Director
ZS
KV
NN
Nanna L?neborg
Director
PT
Peter Thompson
Director
RJ
Robert Jacks
Chief Executive Officer and director
Earlier filings also listed David Katz (executive officer, last listed Jan 2021).